IKK<alpha> and the control of prostate cancer metastasis
IKK<α>与前列腺癌转移的控制
基本信息
- 批准号:7769568
- 负责人:
- 金额:$ 26.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-13 至 2012-02-28
- 项目状态:已结题
- 来源:
- 关键词:AblationAdenocarcinomaAffectAlanineAndrogensArtsBehaviorBinding SitesBiochemicalCancer EtiologyCancer PatientCarcinomaCell LineCell NucleusCell ProliferationCell membraneCellsChimeric ProteinsCollagenCytoplasmDNADendritic CellsDevelopmentDistantDown-RegulationElementsEpithelial CellsEpitheliumFamilyFoundationsGene TargetingGeneticGenetic TranscriptionGlutathione S-TransferaseGoalsGrowthHumanIKK alphaImmunoprecipitationInfiltrationInflammationInflammatoryInterferonsKnock-outLymphocyteMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of prostateMediatingMetastatic Neoplasm to the BoneMethodologyModelingMolecularMouse StrainsMusMutateMutationNeoplasm MetastasisNormal CellNuclear TranslocationOncogenesOperative Surgical ProceduresPathway interactionsPatientsPeptide HydrolasesPhenocopyPhosphorylationPhosphotransferasesPremalignantPrimary NeoplasmProliferatingProstateProstate carcinomaProstatic EpitheliumProstatic NeoplasmsProtease InhibitorProtein BiosynthesisProtein KinaseProteinsProteomicsRadiation therapyRattusRepressionResearchResearch InstituteResidual stateRoleSERPINB5 geneSV40 T AntigensScanningSerine ProteaseSerine Proteinase InhibitorsSignal PathwaySiteSmall Interfering RNASolidSpecimenStagingStromal CellsT-LymphocyteTRANCE proteinTechnologyTestingTrans-ActivatorsTransactTransfectionTumor Cell InvasionTumor Necrosis Factor-BetaTumor PromotionUp-RegulationUpdateUrokinaseWorkactivating transcription factorautocrinebasecancer cellcell typecytokineeffective therapyenhanced green fluorescent proteinextracellularhuman HDAC1 proteinin vitro Assaykillingsmacrophagemalignant breast neoplasmmaspinmembermouse modelmutantnovelnovel therapeutic interventionparacrinepreventprobasinpromoterresearch studyresponsetumortumor progression
项目摘要
DESCRIPTION (provided by applicant): Despite impressive advances in understanding cancer etiology and the development of novel therapeutic approaches, the most effective therapies for solid malignancies (carcinomas) remain surgery and radiotherapy. Although effective in removing and destroying primary tumors, most patients undergoing surgery and radiotherapy will eventually succumb to metastases that develop from residual primary cancer cells that migrate and proliferate at secondary sites. In other words, most cancer patients are killed by metastases rather than the primary tumor. Given the magnitude of this problem, research into the mechanisms that control the metastatic spread of tumors is of utmost importance and urgency This proposal is based on our preliminary results that a mutation that prevents activation of the inflammation responsive protein kinase IkappaB kinase alpha (IKKalpha) results in a dramatic decrease in the metastatic spread of prostate cancer in TRAMP mice, which express a SV40 T antigen oncogene in the prostate epithelium. This reduction in metastatic activity is associated with massive upregulation of maspin, a suppressor of metastasis whose expression is almost completely abolished in primary prostate carcinomas that express the wild type form of IKKalpha. Our preliminary results also suggest that IKKalpha activation results in inhibition of maspin expression. Given its known responsiveness to cytokines produced by stromal cells as well as by inflammatory cells, IKKalpha can provide a major conduit through which the tumor microenvironment controls the metastatic potential of prostate carcinoma cells. Our goal is to test this hypothesis and identify the molecular mechanisms through which IKKalpha controls the metastatic spread of prostate cancer and the expression of maspin in TRAMP mice. We will also examine how the tumor microenvironment modulates the activity of the IKKalpha-maspin axis and will determine the mechanisms through which maspin exerts its anti-metastatic activity in this model of prostate cancer. We will examine whether IKKalpha regulates maspin expression in human prostate cancer specimens and cell lines to control their metastatic and invasive activities. In addition to providing new and important information on the control of tumor metastasis, this work can lay the foundation to the development of novel anti-metastatic therapy based on inhibition of IKKalpha that may be applicable not only to prostate cancer but other cancers as well.
描述(由申请人提供):尽管在了解癌症病因和开发新型治疗方法方面取得了令人印象深刻的进展,但实体恶性肿瘤(癌症)最有效的疗法仍然是手术和放射疗法。虽然可以有效去除和破坏原发性肿瘤,但大多数接受手术和放疗的患者最终会死于残留原发性癌细胞在继发部位迁移和增殖所形成的转移瘤。换句话说,大多数癌症患者是死于转移瘤而不是原发肿瘤。鉴于这个问题的严重性,对控制肿瘤转移扩散的机制的研究至关重要且紧迫。这项提议是基于我们的初步结果,即阻止炎症反应蛋白激酶 IkappaB 激酶 α (IKKalpha) 激活的突变。导致 TRAMP 小鼠前列腺癌的转移性扩散显着减少,该小鼠在前列腺上皮中表达 SV40 T 抗原癌基因。这种转移活性的降低与maspin的大量上调有关,maspin是一种转移抑制因子,其表达在表达野生型IKKalpha的原发性前列腺癌中几乎完全消失。我们的初步结果还表明 IKKalpha 激活会导致 maspin 表达的抑制。鉴于其对基质细胞和炎症细胞产生的细胞因子的已知反应性,IKKalpha 可以提供一个主要管道,通过该管道肿瘤微环境控制前列腺癌细胞的转移潜力。我们的目标是检验这一假设并确定 IKKalpha 控制 TRAMP 小鼠中前列腺癌转移扩散和 maspin 表达的分子机制。我们还将研究肿瘤微环境如何调节 IKKalpha-maspin 轴的活性,并确定 maspin 在前列腺癌模型中发挥其抗转移活性的机制。我们将检查 IKKalpha 是否调节人类前列腺癌标本和细胞系中的 maspin 表达,以控制其转移和侵袭活动。除了提供有关控制肿瘤转移的新的重要信息之外,这项工作还可以为开发基于 IKKalpha 抑制的新型抗转移疗法奠定基础,这种疗法不仅适用于前列腺癌,也适用于其他癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Karin其他文献
Michael Karin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Karin', 18)}}的其他基金
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
NF-kappaB 和线粒体信号作为炎症的正向和负向调节剂
- 批准号:
10516935 - 财政年份:2023
- 资助金额:
$ 26.42万 - 项目类别:
A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy
研究肝内胆管癌发病机制和免疫生物学并改进其免疫治疗的新小鼠模型
- 批准号:
10711615 - 财政年份:2023
- 资助金额:
$ 26.42万 - 项目类别:
Regulation of PDAC metabolism and immunity by collagen and its cleavage products
胶原及其裂解产物对 PDAC 代谢和免疫的调节
- 批准号:
10708168 - 财政年份:2022
- 资助金额:
$ 26.42万 - 项目类别:
Regulation of PDAC metabolism and immunity by collagen and its cleavage products
胶原及其裂解产物对 PDAC 代谢和免疫的调节
- 批准号:
10517874 - 财政年份:2022
- 资助金额:
$ 26.42万 - 项目类别:
The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism
NRF2-FBP1 交叉调节环路以及健康和患病肝脏代谢的控制
- 批准号:
10503841 - 财政年份:2022
- 资助金额:
$ 26.42万 - 项目类别:
The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism
NRF2-FBP1 交叉调节环路以及健康和患病肝脏代谢的控制
- 批准号:
10670920 - 财政年份:2022
- 资助金额:
$ 26.42万 - 项目类别:
The effect of cancer cell produced collagen 1 homotrimers on DDR1 signaling activation by microenvironmental collagen 1 fragments.
癌细胞产生的胶原蛋白 1 同源三聚体对微环境胶原蛋白 1 片段激活 DDR1 信号传导的影响。
- 批准号:
10831212 - 财政年份:2022
- 资助金额:
$ 26.42万 - 项目类别:
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
NF-kappaB 和线粒体信号作为炎症的正向和负向调节剂
- 批准号:
10182897 - 财政年份:2020
- 资助金额:
$ 26.42万 - 项目类别:
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
NF-kappaB 和线粒体信号作为炎症的正向和负向调节剂
- 批准号:
10266224 - 财政年份:2020
- 资助金额:
$ 26.42万 - 项目类别:
Control of Lipogenesis and Hepatic Steatosis by Caspase-2
Caspase-2 对脂肪生成和肝脂肪变性的控制
- 批准号:
10322660 - 财政年份:2019
- 资助金额:
$ 26.42万 - 项目类别:
相似国自然基金
HA依赖的糖被调节乳腺癌细胞膜张力对细胞干性化影响的机制研究
- 批准号:82372710
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
LncRNA-DKFZP434K028调控HNRNPA2B1影响乳腺癌细胞外泌体miR-939的包装和释放促进肿瘤相关巨噬细胞M2极化的分子机制研究
- 批准号:82373043
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
CRL3 E3泛素连接酶调控SLC7A11稳定性从而诱导铁死亡影响乳腺癌发生发展的作用和机制研究
- 批准号:82372688
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
糖萼形成蛋白MUC15通过与整合素物理相互作用影响integrin β1/FAK/YAP力信号轴的机械转导调控胰腺癌转移的机制研究
- 批准号:82303455
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MGST1通过SPG7影响甲状腺癌中调节性T细胞功能的机制研究
- 批准号:82303152
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma
靶向 HNF1A 介导的胰腺导管腺癌治疗耐药
- 批准号:
10561370 - 财政年份:2023
- 资助金额:
$ 26.42万 - 项目类别:
Dissecting Neuro-Immune Interactions in Cancer
剖析癌症中的神经免疫相互作用
- 批准号:
10722350 - 财政年份:2023
- 资助金额:
$ 26.42万 - 项目类别:
Investigating the role of SHP2-PLCG1 interaction in PDAC calcium signaling and metabolism
研究 SHP2-PLCG1 相互作用在 PDAC 钙信号传导和代谢中的作用
- 批准号:
10752562 - 财政年份:2023
- 资助金额:
$ 26.42万 - 项目类别:
Deciphering the Molecular Genetics of VSIG10L in Barrett's Neoplasia
破译巴雷特瘤形成中 VSIG10L 的分子遗传学
- 批准号:
10713939 - 财政年份:2023
- 资助金额:
$ 26.42万 - 项目类别:
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
阐明癌症相关 FGL1 在肿瘤免疫中的作用并开发 FGL1 引导的抗 LAG-3 癌症免疫疗法
- 批准号:
10504399 - 财政年份:2022
- 资助金额:
$ 26.42万 - 项目类别: